Navigation Links
Drugs from Biogen Idec and Merck are the Most Promising Therapies in Development in the Acute Heart Failure Market
Date:2/2/2009

Overall Market for Acute Heart Failure Therapies Will More Than Double to $768 Million in 2017, According to a New Report from Decision Resources

WALTHAM, Mass., Feb. 2 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Biogen Idec's Adentri and Merck's rolofylline are the most promising therapies in development for acute heart failure, according to surveyed experts. Scios/Johnson & Johnson's Natrecor and Daiichi Sankyo's Hanp have also added considerable value to the acute heart failure market in recent years and will continue to do so through 2017.

The new Pharmacor report entitled Acute Heart Failure finds that the launch of Adentri and rolofylline, along with EKR Therapeutics' ularitide, will be the primary drivers of growth in the acute heart failure drug market over the next decade. Growth will also be driven by an increase in the number of diagnosed events of acute heart failure as a result of the rising population of elderly people, improved diagnosis methods and increased survival following acute myocardial infarction.

The report forecasts that the acute heart failure market will more than double, from $354 million in 2007 to $768 million in 2017 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. The market for acute heart failure is modestly sized because the dominant therapies -- loop diuretics and nitrate vasodilators -- are some of the oldest agents in cardiology and, as a result, are generically available and inexpensive.

"Despite the significant unmet need, research and development pipelines for acute heart failure are not as robust as those for other cardiovascular indications such as hypertension and dyslipidemia," said Decision Resources Analyst Amir Mobasheri. "As a result, any novel agent that can demonstrate improvements in safety and mortality and shows efficacy in preventing future acute heart failure episodes will be well received by physicians and patients."

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained

in this document may be trademarks or registered trademarks of their

respective holders.

    For more information, contact:

    Decision Resources                        Decision Resources, Inc.
    Christopher Comfort                       Elizabeth Marshall
    781-296-2597                              781-296-2563
    ccomfort@dresources.com                   emarshall@dresources.com

'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. New review suggests caution on drugs to raise good cholesterol
2. Can cancer drugs combine forces?
3. Study provides hope that some transplant patients could live free of antirejection drugs
4. Study provides hope that some transplant patients could live free of anti-rejection drugs
5. RA Drugs Linked to Slight Skin Cancer Risk
6. Report on patients access to cancer drugs uses flawed methods to reached flawed conclusions
7. Rock N Roll: Sex, Drugs and an Early Exit
8. Australian-led international study shows blood pressure drugs cut death rate in type 2 diabetes
9. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
10. Are Bargaining Groups Hired by Independent Drugstores Causing Payment Delays to Pharmacies?
11. 2 drugs equally effective for heart patients undergoing angioplasty, Mayo study finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... , ... February 20, 2017 , ... ... now available as an employee health benefit for companies that want to help ... clinical consultation providers, employees will have access to Watson’s suite of oncology offerings ...
(Date:2/20/2017)... ... February 20, 2017 , ... Houston dentist , Dr. ... care at his office, Antoine Dental Center. Emergency dentistry encompasses many treatments for ... at risk for serious complications and often experience severe pain. Not only does ...
(Date:2/20/2017)... , ... February 20, 2017 , ... Chuck E. Cheese’s® ... Sensitive Sundays, a joint event at Chuck E. Cheese’s locations throughout New England, New ... special needs, the opportunity to experience the fun of visiting Chuck E. Cheese’s in ...
(Date:2/20/2017)... ... February 20, 2017 , ... Florida Hospital Pepin Heart ... ultrasound-enhanced thrombolysis machine, a state-of-the-art device that breaks up life-threatening blood clots by ... Family Foundation. , “We greatly appreciate this gift from Constellation Brands. We are ...
(Date:2/19/2017)... Wert, OH (PRWEB) , ... February 19, 2017 , ... ... as The JEMS Conference & Exposition, the event will take place February 23-25, 2017 ... Braun Industries will be in Booth #909 with three new ambulances on ...
Breaking Medicine News(10 mins):
(Date:2/20/2017)... Feb. 20, 2017   Orion Health ™ ... Amadeus precision medicine platform to the Amazon Web ... over 110 million patient records globally. "We ... big data solutions built on modern, scalable technology," said ... Life Sciences. "The AWS Cloud gives healthcare companies a ...
(Date:2/20/2017)... Research and Markets has announced the addition ... and Trends - Product (RFID refrigerators and RFID freezers), Application (Diagnostic ... to their offering. ... The Global RFID Blood Refrigerator and Freezer Market is poised ... 2025. This industry report analyzes the global markets ...
(Date:2/20/2017)... , Feb. 20, 2017   Alberty ... Batavia, NY has announced a ... their compounding and wellness programs to servicing local Veteran ... constraints on budgets and an increased need to secure ... are looking to source locally for their goods & ...
Breaking Medicine Technology: